Investor overview

Scandion Oncology was established to address one of the most important problems in modern oncology: the treatment of cancers that have developed resistance to chemotherapy.

What makes Scandion Oncology an attractive company for investors?

  • Limited investment horizon: Clinical Phase II studies will be completed within 3 years after investment.
  • Potential high return: Detailed analyses from Cortris show that the current market for the chosen indications is more than EUR 4 billion in annual peak sales.
  • Strong assets with patent rights: The patents underlying our two major products in development expire in 2036 and 2037.
  • High unmet medical needs: More than 14 million new cases of cancer every year on a worldwide scale. Half of all patients who receive chemotherapy become resistant.
  • Experienced management team: Our executive team includes a CEO with more than 25 years of biotech and pharma experience and a CSO who has authored more than 70 publications, the majority focusing on translational cancer research, biomarkers and drug resistance.
  • Robust pipeline: Scandion Oncology has two major assets under development, SCO-101 and SCO-201, and more than 800 analogues for the future. The target indications for the analogues are solid tumors.
  • Strong clinical data: Our lead product – SCO-101 – has successfully passed four Phase I trials without showing toxicity.
  • Multiple indications: In addition to our lead product SCO-101 targeting metastatic breast cancer and colorectal cancer, we are simultaneously developing SCO-201, which will target other solid tumors.


Reports & Presentations

Interim reports
Year-end reports
Annual reports

Corporate Governance

General meeting
Articles of Association
Incentive program


Scandion Oncology has a strong patent portfolio lasting until 2037.
We believe our patents are attractive for larger pharmaceutical companies to combine with their existing cancer treatments.

Share information

Share price


Trading abbreviation

Number of shares
7.463.207 (before IPO)

First day of trading
First day of trading in the share is planned to be November 8, 2018.

Investor Relations

Financial Calendar

22.Nov 18

Quarterly statement Q3, 2018

21.Feb 19

Year-End Report 2018

29.Apr 19

Annual report published

Week 18 (April 29 – May 3, 2019)

23.May 19

Quarterly statement Q1, 2019

29.May 19

Annual general meeting

22.Aug 19

Semi-annual Report Q2, 2019

21.Nov 19

Quarterly statement Q3, 2019

Quarterly statement Q3, 2019